AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04972383 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: In the Hyaluronic group, 3mLHYAJOINT Plus was given.
Study NCT03487224 — intervention group
Intervention type: DEVICE
Intervention: MRI with fMRI frequency
Description: Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
Study NCT02983084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic archwire
Description: Archwire used to align teeth in an orthodontic fixed appliance
Study NCT00730990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission tomography
Description: Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
Study NCT00730990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET Scan with PF-03654746
Description: If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
Study NCT02983084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic archwire
Description: Archwire used to align teeth in an orthodontic fixed appliance
Study NCT04237649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAZ954
Description: KAZ954 will be administered in every arm.
Study NCT04237649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: KAZ954 + PDR001
Study NCT04237649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: KAZ954 + NIR178
Study NCT04237649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NZV930
Description: KAZ954 + NZV930
Study NCT00942162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2132231A
Description: Intramuscular administration
Study NCT00730990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET Scan with PF-03654746
Description: If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
Study NCT00730990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET Scan with PF-03654746
Description: Part 2 of the study will have 3 possible interventions:~1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg).
Study NCT03847779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: Cutaneous perfusion and vasomotion assessment at rest in supoine position
Study NCT02917525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Study NCT02917525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03777826 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PKU Synergy
Description: PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
Study NCT02460653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC Flow Rate
Description: We only change the flow rates between low, medium and high settings.
Study NCT04325789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nanofiber scaffold
Description: Utilization of the interpositional nanofiber scaffold to augment the rotator cuff repair.
Study NCT03724747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2315497 Injection
Description: BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
Study NCT03724747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide(BAY1841788)
Description: 600 mg (2 X 300 mg tablets), twice daily with food, equivalent to a total daily dose of 1200 mg.
Study NCT06526468 — intervention group
Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: AI technology will provide novel imaging markers and generate a radiology report with relevant key slice imaging and evaluation results
Study NCT01419067 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical Surgery or Limited Surgery
Description: Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
Study NCT01419067 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Proton Therapy
Description: Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
Study NCT01419067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ^1^8F-fluorodeoxyglucose
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Study NCT01419067 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ^1^1C-methionine
Description: This is a contrast media that will be given intravenously to aid in tumor visualization.
Study NCT03941444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Description: Liquid oral solution
Study NCT01730638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: • TF2 and 68 Ga-IMP-288
Study NCT03847779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test
Study NCT03847779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot lowering
Description: Cutaneous perfusion and vasomotion assessment after foot lowering
Study NCT03847779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Cutaneous perfusion and vasomotion assessment during hyperthermia
Study NCT03941444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid oral solution
Study NCT02833311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Tablet Group
Description: A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
Study NCT00437125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine hydrochloride
Description: Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
Study NCT02833311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper and Pencil Group
Description: Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
Study NCT02833311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contact Control Group
Description: Participants are prescribed an exercise program and given information on healthy eating.
Study NCT00509886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drysol
Description: 20% aluminum chloride hexahydrate
Study NCT00509886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drioff
Description: 1% aluminum acetate
Study NCT01823562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lyophilized black raspberry confection
Description: Given PO
Study NCT01823562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01823562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01823562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: Follow a low polyphenol diet
Study NCT01823562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: Follow a low ellagitannin diet
Study NCT01823562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: Follow a low ellagitannin diet
Study NCT04196335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-procedural intracardiac echocardiography
Description: use of intra-procedural intracardiac echocardiography during Watchman FLX devices
Study NCT03936101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prenatal Genomic Sequencing
Description: Whole genome sequencing (which initially will be masked and reported as exome only)
Study NCT03208374 — intervention group
Intervention type: BEHAVIORAL
Intervention: Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire
Description: Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
Study NCT03208374 — intervention group
Intervention type: BEHAVIORAL
Intervention: Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)
Description: The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
Study NCT03824691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: cabozantinib 40 mg orally once daily
Study NCT03824691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg durvalumab (MEDI4736) IV infusion every 28 days
Study NCT02561845 — intervention group
Intervention type: DRUG
Intervention: rosuvastatin
Description: 5mg, 10mg, 20mg
Study NCT00032487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
Study NCT00032487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
Study NCT00032487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
Study NCT00032487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
Study NCT00032487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
Study NCT01823562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01823562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01823562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01823562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02626338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Study NCT02626338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT02626338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02626338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02626338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT02626338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT02626338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Study NCT00032487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
Study NCT00032487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
Study NCT03951987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 ml CG5503
Description: 4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
Study NCT03951987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 g charcoal powder
Description: Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
Study NCT00919659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: parenteral nutrition
Description: 25kcal/kg bw with parenteral nutrition
Study NCT02803034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987516)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Number- SR15-60-Z15-030).
Study NCT00087295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depsipeptide
Description: Depsipeptide wil be given 13 mg/m\^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
Study NCT02545803 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Near-Infrared Spectroscopy (NIRS)
Description: Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
Study NCT00849030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastozole (Arimidex)
Description: 1mg, orally, once daily
Study NCT00896233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRE
Description: Part 1: Participants will have a screening visit, followed \~1 month later by two imaging visits over \~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed \~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans.
Study NCT04174742 — intervention group
Intervention type: DRUG
Intervention: pegfilgrastim
Description: It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
Study NCT04885439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NextSteps
Description: Intervention sessions are delivered by a Masters level trained interventionist. During sessions, the interventionist will: conduct the weekly symptom screen, review content, answer questions, ensure skills mastery through homework review, and work with participants to develop action plans and identify/overcome barriers to self-care/caregiving. Patients and caregivers will receive individual calls from the interventionist for sessions 1, 2, and 3, and participate together for sessions 4, 5, and 6 via speakerphone.
Study NCT01284192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3026
Description: Tablet
Study NCT01671904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter \[mg/m\^2\]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
Study NCT01016899 — intervention group
Intervention type: RADIATION
Intervention: electronic brachytherapy
Description: Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
Study NCT03204695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous LAA Closure
Description: LAA Closure with the WaveCrest LAA Occlusion System (study device)
Study NCT03204695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation or Clopidogrel
Description: Subjects either continue on anticoagulation or receive clopidogrel
Study NCT01817634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish powder corn-soy blend'+ Fish oil capsule.
Description: Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
Study NCT01817634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish powder corn-soy blend + corn oil capsule.
Description: Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
Study NCT01817634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn-soy blend + fish oil capsule.
Description: control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
Study NCT01817634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy blend + corn oil capsule.
Description: control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
Study NCT01628302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lowering salt in diet
Description: Low salt diet (50mmol)for three weeks.
Study NCT02790216 — intervention group
Intervention type: PROCEDURE
Intervention: Brachytherapy
Description: Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
Study NCT03990714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right hemicolectomy
Description: It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
Study NCT01671904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV infusion of obinutuzumab (100 milligrams \[mg\]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
Study NCT01671904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV infusion of rituximab (375 mg/m\^2) on Day 1 of Cycle 1 and 500 mg/m\^2 administered on Day 1 of Cycles 2-6.
Study NCT01671904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive multiple doses of venetoclax orally once daily.
Study NCT01587963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: 66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
Study NCT01587963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ringers Lactate or Normal Saline
Description: Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
Study NCT01613612 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: core decompression
Description: minimal surgical invention to drill a core to the femoral head to release pressure